Dr. Freeman is an entrepreneur and physician and has served most recently as a Venture Partner at GreatPoint Ventures. He is the founder of Zafgen, a venture-backed company developing new therapeutics for obesity based on targeting the vasculature, and served as the company’s founding Vice President of Business Development. He was formerly an Engagement Manager at MEDACorp (now Leerink Swann Strategic Advisors), where he advised pharmaceutical and biotechnology companies on strategic acquisitions, in-licensing, pipeline prioritization, and clinical development. Previously he worked with the Neuroscience Clinical Development group at Wyeth and in medical diagnostics development at Mitsubishi Pharma. Dr. Freeman performed his clinical training in neurology at the University of Pennsylvania, obtained his medical degree and Masters in Molecular Cell Biology from Washington University in St. Louis, and completed his undergraduate work at MIT. Dr. Freeman is an entrepreneur and physician and has served most recently as a Venture Partner at GreatPoint Ventures. He is the founder of Zafgen, a venture-backed company developing new therapeutics for obesity based on targeting the vasculature, and served as the company’s founding Vice President of Business Development. He was formerly an Engagement Manager at MEDACorp (now Leerink Swann Strategic Advisors), where he advised pharmaceutical and biotechnology companies on strategic acquisitions, in-licensing, pipeline prioritization, and clinical development. Previously he worked with the Neuroscience Clinical Development group at Wyeth and in medical diagnostics development at Mitsubishi Pharma. Dr. Freeman performed his clinical training in neurology at the University of Pennsylvania, obtained his medical degree and Masters in Molecular Cell Biology from Washington University in St. Louis, and completed his undergraduate work at MIT.

Radiology, Oncology, Cancer research